New York-based biopharmaceutical company Kadmon Holdings Inc. divested some of its shareholding in MeiraGTx Holdings PLC.
The shareholder sold about 1.4 million MeiraGTx shares for $22 million in net proceeds to repay some of its debt and generate funds for corporate purposes. The company continues to hold 2.1 million shares of New York-based MeiraGTx, a gene therapy company developing treatments for various diseases including inherited blindness, different types of cancers and neurodegenerative diseases.
